Research Updates
Evidence-based research compiled from PubMed for peptide therapies.
Important Research Limitations
The majority of peptide research comes from preclinical (animal) studies. Human clinical trial data is limited. Always consult a healthcare provider before considering any peptide therapy.
BPC-157 Gut Healing Research
Compiled from PubMed: 13 peer-reviewed studies on BPC-157's effects on gastrointestinal healing.
Gut Healing Evidence
All gut healing evidence comes from animal (rat) studies. No published human clinical trials for gut healing as of December 2024.
IBD Clinical Trials
Identifiers: PL-10, PLD-116, PL 14736
Safety Profile
No reported toxicity in animal studies. LD1 not achieved. Safe in human trials conducted.
Key Mechanisms of Action
Angiogenesis
Rapid recruitment of blood vessels toward injury sites, promoting tissue repair
PMIDs: 38583442, 30622376, 9403790
NO-System Modulation
Interacts with nitric oxide pathways, counteracting both L-NAME and L-arginine effects
PMIDs: 27895400, 30622376, 28228068
Cytoprotection
Provides cellular protection against various damaging agents including NSAIDs and stress
PMIDs: 38583442, 22950504, 28228068
Collagen Formation
Stimulates collagen synthesis and granulation tissue formation for wound healing
PMIDs: 9403790, 21548867
Gene Expression Modulation
Affects NOS-2, COX-2, VEGF-A, and other genes involved in healing
PMIDs: 38583442, 28228068
Conditions Studied
| Condition | Evidence Level | Study Model | Studies |
|---|---|---|---|
| Intestinal anastomosis healing | moderate | rat | 5 |
| Fistula healing (various types) | moderate | rat | 4 |
| Colitis/IBD | moderate | rat + phase-2 human | 3 |
| NSAID-induced GI damage | moderate | rat | 3 |
| Short bowel syndrome | low | rat | 2 |
| Gastric ulcers | moderate | rat | 5 |
Published Studies
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review
Bajramagic S, Sever M, Rasic F, et al.
Pharmaceuticals (Basel) 17(8)
Comprehensive review of BPC 157 therapy in various intestinal anastomoses healing in rats.
Key Outcomes:
- Promotes healing of esophagogastric, colocolonic, jejunoileal, and ileoileal anastomoses
- Counteracts associated disturbances including esophagitis and sphincter dysfunction
- Addresses failed intestinal adaptation and short bowel syndrome
- Heals both external and internal fistulas
Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME
Djakovic Z, Djakovic I, Cesarec V, et al.
World J Gastroenterol 22(41):9127-9140
BPC 157 therapy eliminated mortality and fully counteracted esophagogastric anastomosis complications in rats.
Key Outcomes:
- Eliminated mortality from esophagogastric anastomosis
- Counteracted esophagitis and sphincter dysfunction
- Maintained blood vessel presence at gastric surface
- Interacts with NO-system for enhanced healing
Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint
Vukusic D, Zenko Sever A, Sever M, et al.
J Physiol Pharmacol 75(1)
BPC 157 rapidly induced vessel recruitment and healed duodenocolic fistulas via cytoprotection mechanisms.
Key Outcomes:
- Rapid vessel recruitment toward defect sites
- Closed both duodenal and colonic defects
- No fistula leakage or cachexia
- Elevated NOS-2 and decreased COX-2, VEGF-A expression
Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula
Grgic T, Grgic D, Drmic D, et al.
Eur J Pharmacol 780:1-7
BPC 157 induced full healing of colovesical fistulas with both colon and vesical defects simultaneously healed.
Key Outcomes:
- Full healing of colovesical fistulas
- Simultaneous healing of colon and vesical defects
- Counteracted adhesion formation and intestinal obstruction
- Effective via oral or intraperitoneal administration
Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats
Baric M, Zenko Sever A, Batelja Vuletic L, et al.
Life Sci 148:63-70
BPC 157 achieved full healing of rectovaginal fistulas with improved macroscopic and microscopic findings.
Key Outcomes:
- Full healing of rectovaginal fistulas
- Both rectal and vaginal defects healed simultaneously
- Reduced adhesion formation and intestinal obstruction
- Effective in μg and ng dose ranges
Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries
Klicek R, Kolenc D, Suran J, et al.
J Physiol Pharmacol 64(5):597-612
BPC 157 induced efficient healing of cysteamine colitis and colon-colon anastomosis, linking IBD and MS therapy.
Key Outcomes:
- Efficient healing of cysteamine-induced colitis
- Healed colon-colon anastomosis
- Counteracted cuprizone-induced brain injuries
- Demonstrated link between IBD and multiple sclerosis models
Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157
Sikiric P, Seiwerth S, Rucman R, et al.
Curr Med Chem 19(1):126-132
Review of BPC 157 as therapy for IBD, highlighting its stability in gastric juice and wound healing effects.
Key Outcomes:
- Stable in human gastric juice
- Effective in upper and lower GI tract
- Promotes wound healing and angiogenesis
- Interacts with NO-system for endothelium protection
- Clinical phase II trials conducted for IBD (PL 14736)
Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine
Drmic D, Samara M, Vidovic T, et al.
World J Gastroenterol 24(48):5462-5476
BPC 157 markedly increased vessel presentation, narrowed defects, and shortened bleeding time in perforated cecum model.
Key Outcomes:
- Increased vessel recruitment toward injury site
- Narrowed defect size significantly
- Shortened bleeding time
- Normalized MDA and NO levels
- Therapeutic effect achieved alone or with L-NAME/L-arginine
Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats
Gojkovic S, Krezic I, Vrdoljak B, et al.
World J Gastrointest Pathophysiol 11(1):1-19
BPC 157 counteracted Budd-Chiari syndrome in rats by activating bypassing pathways and reducing GI lesions.
Key Outcomes:
- Activated bypassing pathways between inferior and superior caval veins
- Counteracted caval/portal hypertension
- Reduced stomach and duodenum hemorrhages
- Attenuated thrombosis and reduced liver pathology
Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?
Sikiric P, Seiwerth S, Rucman R, et al.
Curr Pharm Des 23(27):4012-4028
Comprehensive review positioning BPC 157 as integrative mediator of stress response from the GI tract.
Key Outcomes:
- Native in gastrointestinal tract
- Stability in human gastric juice
- Cytoprotection/adaptive cytoprotection/organoprotection
- Counteracts NSAIDs side effects
- Affects dopamine, serotonin, GABA, and NO systems
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al.
Curr Pharm Des 17(16):1612-1632
Review of BPC 157 as anti-ulcer peptidergic agent with applications across the entire GI tract.
Key Outcomes:
- Effective in esophagitis with sphincter function rescue
- Heals intestinal anastomosis and fistulas
- Reversed short bowel syndrome
- Strong angiogenic potential
- Protects endothelium and prevents thrombosis
Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157
Sikiric P, Seiwerth S, Rucman R, et al.
Curr Pharm Des 19(1):76-83
Review of BPC 157 as potential antidote against NSAIDs-induced GI and systemic toxicity.
Key Outcomes:
- Counteracts NSAID-induced stomach, duodenum, intestine lesions
- Protects liver and brain from NSAID injury
- Counteracts aspirin-induced prolonged bleeding
- No reported toxicity (LD1 not achieved)
- Equipotent at μg and ng/kg doses
BPC 157's effect on healing
Seiwerth S, Sikiric P, Grabarevic Z, et al.
J Physiol Paris 91(3-5):173-178
Early study demonstrating BPC 157 promotes granulation tissue, angiogenesis, and collagen formation.
Key Outcomes:
- Promotes granulation tissue formation
- Enhances angiogenesis
- Increases collagen production
- Improves tensile strength in wounds
- Effective via intragastric and local application
Research Disclaimer
IMPORTANT RESEARCH LIMITATIONS: 1. PRECLINICAL EVIDENCE: The majority of BPC-157 gut healing research comes from animal studies (primarily rats). Human clinical trial data for gut healing applications has not been published in peer-reviewed journals. 2. SINGLE RESEARCH GROUP: Much of the published research originates from the University of Zagreb research group. Independent replication by other institutions is limited. 3. NOT FDA APPROVED: BPC-157 is not FDA-approved for any indication. It is classified as a research peptide. 4. MEDICAL SUPERVISION REQUIRED: Any use of BPC-157 should be under the supervision of a qualified healthcare provider. 5. EVIDENCE HIERARCHY: Animal studies provide preliminary evidence but do not guarantee efficacy or safety in humans. Results should be interpreted with appropriate caution.